T1	Participants 55 72	autistic disorder
T2	Participants 308 359	pediatric subjects receiving aripiprazole treatment
T3	Participants 550 609	pediatric subjects with autistic disorder, aged 6-17 years.
T4	Participants 913 937	316 randomized subjects,
T5	Participants 2092 2108	younger subjects
T6	Participants 2397 2445	children and adolescents with autistic disorder.